Palisade Bio, Inc.
PALI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001357459
In the last 90 days, Palisade Bio, Inc. insiders filed 3 open-market purchases and 2 sales; 124 institutions reported holding it in 13F filings for Q2 2026, worth $362.4M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Palisade Bio, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 124
- +29 vs. Q1 2026
- Shares held
- 173.4M
- +34.6M (+24.9%) vs. Q1 2026
- Total value
- $362.4M
- +$119.4M (+49.2%) vs. Q1 2026
- New holders
- 50
- 33 more added
- Sold out
- 21
- 24 more reduced
1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PALI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 124 | $362.4M |
| Q1 2026 | 96 | $261.7M |
| Q4 2025 | 86 | $319.4M |
| Q3 2025 | 12 | $102.8K |
| Q2 2025 | 11 | $57.5K |
| Q1 2025 | 13 | $200.9K |
| Q4 2024 | 10 | $387.7K |
| Q3 2024 | 9 | $347.4K |
| Q2 2024 | 8 | $297.7K |
| Q1 2024 | 16 | $384.6K |
| Q4 2023 | 16 | $158.3K |
| Q3 2023 | 13 | $86.6K |
| Q2 2023 | 11 | $228.7K |
| Q1 2023 | 9 | $29.8K |
| Q4 2022 | 12 | $648.0K |
| Q3 2022 | 33 | $842.0K |
| Q2 2022 | 26 | $395.0K |
| Q1 2022 | 25 | $930.0K |
| Q4 2021 | 28 | $1.70M |
| Q3 2021 | 22 | $2.03M |
| Q2 2021 | 23 | $10.1M |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Palisade Bio, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Great Point Partners LLC | 2,284,819 | $4.78M | 1.13% | −1,120,938−32.9% | Reduced |
| OrbiMed Advisors LLC | 2,333,000 | $4.88M | 0.09% | 00.0% | Unchanged |
| Morgan Stanley | 2,474,069 | $5.17M | 0.00% | −2,077,464−45.6% | Reduced |
| State Street Corp | 2,475,648 | $5.17M | 0.00% | +1,839,451+289.1% | Added |
| Vestal Point Capital, LP | 2,500,000 | $5.22M | 0.12% | 00.0% | Unchanged |
| Propel Bio Management, LLC | 2,582,388 | $5.40M | 2.82% | +1,467,388+131.6% | Added |
| Squadron Capital Management LLC | 3,000,000 | $6.27M | 2.15% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 3,136,607 | $6.56M | 0.01% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 3,578,020 | $7.48M | 0.00% | −1,795,931−33.4% | Reduced |
| Wellington Management Group LLP | 3,703,936 | $7.74M | 0.00% | +799,025+27.5% | Added |
| Geode Capital Management, LLC | 3,760,485 | $7.86M | 0.00% | +2,214,245+143.2% | Added |
| Eversept Partners, LP | 4,182,785 | $8.74M | 0.48% | −804,714−16.1% | Reduced |
| Adage Capital Partners GP, L.L.C. | 4,500,000 | $9.40M | 0.01% | 00.0% | Unchanged |
| Boxer Capital Management, LLC | 4,799,875 | $10.0M | 0.76% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 5,253,403 | $11.0M | 0.02% | +4,841,631+1,175.8% | Added |
| Franklin Resources Inc | 5,785,189 | $12.1M | 0.00% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 7,124,116 | $14.9M | 0.13% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 8,425,065 | $17.6M | 0.27% | −503,084−5.6% | Reduced |
| Octagon Capital Advisors LP | 10,276,317 | $21.5M | 1.97% | 00.0% | Unchanged |
| BlackRock, Inc. | 10,436,760 | $21.8M | 0.00% | +8,560,420+456.2% | Added |
| Jupiter Topco LLC | 10,689,452 | $22.4M | 0.01% | +10,689,452 | New |
| Ameriprise Financial Inc | 11,081,434 | $23.2M | 0.00% | −428,886−3.7% | Reduced |
| B Group, Inc. | 11,414,285 | $23.9M | 13.54% | 00.0% | Unchanged |
| Soleus Capital Management, L.P. | 13,063,687 | $27.3M | 0.94% | +13,063,687 | New |
| Commodore Capital LP | 0 | $0 | 0.00% | −7,181,062−100.0% | Sold out |
| Exome Asset Management LLC | 0 | $0 | 0.00% | −600,000−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −410,761−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −214,821−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −211,882−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −148,970−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −133,131−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −105,832−100.0% | Sold out |
| Hudson Bay Capital Management LP | 0 | $0 | 0.00% | −89,386−100.0% | Sold out |
| Omers Administration Corp | 0 | $0 | 0.00% | −83,300−100.0% | Sold out |
| Diametric Capital, LP | 0 | $0 | 0.00% | −51,874−100.0% | Sold out |
| Vontobel Holding Ltd. | 0 | $0 | 0.00% | −45,000−100.0% | Sold out |
| Jefferies Financial Group Inc. | 0 | $0 | 0.00% | −34,875−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −33,146−100.0% | Sold out |
| Catalyst Funds Management Pty Ltd | 0 | $0 | 0.00% | −31,400−100.0% | Sold out |
| CTC Alternative Strategies, Ltd. | 0 | $0 | 0.00% | −17,441−100.0% | Sold out |
| Commonwealth Equity Services, LLC | 0 | $0 | 0.00% | −16,500−100.0% | Sold out |
| LMR Partners LLP | 0 | $0 | 0.00% | −15,400−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −15,346−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −12,177−100.0% | Sold out |
| RFG Advisory, LLC | 0 | $0 | 0.00% | −11,750−100.0% | Sold out |
| Janus Henderson Group PLC | – | – | – | – | Not filed |